Novel Diagnostic and Management Strategies in Coronary Microvascular Angina Pectoris

Microvascular angina, also known as cardiac syndrome X, refers to as a situation where a person experiences chest pain despite normal coronary arteries as viewed during angiography. There are symptoms of decreased coronary blood flow, like ECG changes associated with exercise or stress testing, present in this case [1]. Coronary microvascular dysfunction (CMD) is the major pathophysiological theory, in spite of angiographically normal large-vessel anatomy, it is caused by small-vessel endothelial dysfunction and poor vascular reactivity [2]. Autonomic instability, increased pain perception and chronic systemic inflammation, are other contributing factors [3].

HISTORICAL BACKGROUND 

This syndrome was first described in 1967 by Likoff and a group of women who had normal coronary angiograms, ischemia ECG alterations during exercise, and chest discomfort [4]. Harvey Kemp had given the term "Syndrome X" in 1973 to describe this illness, which is categorized by angina symptoms with normal angiography and unknown causes [5]. The word "microvascular angina" was first used in the 1980s by researchers named Cannon and Epstein, which mainly focused on endothelial dysfunction and reduced coronary flow reserve in small arteries even in the absence of epicardial blockage [6]. In the following decades the knowledge changed from assigning symptoms to benign causes such as anxiety or dyspepsia to realize that myocardial ischemia was caused by microvascular disease [7].

PREVALENCE / EPIDEMIOLOGY 

Up to 49% of patients having angiography for suspected ischemia show no obstructive CAD, and among these, up to 60–64% exhibit signs of CMD consistent with MVA, according to observational cohort studies [8]. The prevalence of CMD was shown to be roughly 51–54% in a large PET-based investigation with over 1,200 participants, with equal rates for males (51%) and women (54%) [9]. According to other CCD (coronary reactivity) based cohorts, the prevalence was

63% in mixed-gender groups without obstructive lesions and 47% in women [10]. Together, these findings imply that microvascular dysfunction may be the cause of symptoms in approximately 50% of ischemia patients without macrovascular illness [11].

RISK FACTORS 

A significant risk factor is female sex: around 60–70% of cardiac syndrome X or MVA cohorts are female, and among patients assessed for angina with normal coronaries, 41% of women and 8% of men showed non-obstructive illness, which is consistent with MVA [12]. Macrovascular disease and cardiovascular risk factors are similar: individuals with MVA often have high blood pressure, high cholesterol, smoking, insulin resistance, obesity, and estrogen shortage (e.g., postmenopausal condition) [13]. Insulin resistance and metabolic syndrome are especially closely related. MVA was linked to metabolic syndrome characteristics as insulin resistance, dyslipidemia, and hypertension in 14% of a cohort of 500 patients having angiography who had symptoms and normal angiograms (mostly perimenopausal women) [14]. Endothelial dysfunction has been linked to symptoms in Syndrome X/MVA patients, as evidenced by elevated plasma endothelin-1 and decreased nitric oxide bioavailability [15]. 

ETIOLOGY OF MICROVASCULAR ANGINA PECTORIS 

The underlying cause of MVA, coronary microvascular dysfunction (CMD), is caused by a combination of anatomical and functional disease in the small coronary resistance channels (<300 µm), which results in angina and poor perfusion even in the presence of patent epicardial arteries

[16].

 

 

(Figure 1)

 

 

(Figure 2)

 

 

(Figure 3)

 Whether or not a person has blockages in the main coronary arteries, CMD can still happen. However, when obstructive coronary artery disease (CAD) is not present, studying CMD is frequently simpler. This is due to the fact that when blockages are present, it becomes challenging to determine whether the blockage or CMD is the reason of the decreased blood flow. Doctors can confidently associate CMD with decreased blood flow or aberrant coronary flow reserve (CFR) by using CT angiography to rule out obstructive CAD.

Cardiac PET (Positron Emission Tomography) is the most accurate and dependable imaging modality for identifying CMD [43].

Echocardiography  

One study examined 70 individuals, 44 of whom were female, who had chest pain but no coronary artery blockages. These patients underwent a number of procedures, including stress echocardiography, radionuclide scans, treadmill stress testing, and thallium imaging. Surprisingly, the researchers discovered that the results varied between tests. While some tests revealed anomalies in the heart muscle or symptoms of ischemia, others did not. There were no obvious problems with heart wall motion, despite the patients' chest discomfort and ECG abnormalities. This demonstrates how difficult it is to diagnose CMD [44]. During a routine echocardiography scan, physicians examine the flow in the left anterior descending (LAD) artery using color Doppler imaging.

 A modified image that displays the LAD going along the front of the heart is typically used to do this [45].

PET (Peripheral Endothelial Testing)

PET scans are advanced method of detecting the cardiac muscle's blood flow. Doctors can monitor blood flow and obtain specific measures by using specialized tracers. This tracer includes 13N-ammonia, 82Rb-rubidium, 18F-flurpiridaz, and 15O-water which enables accurate monitoring of blood flow in different cardiac regions [46]. Using drugs like adenosine or dobutamine to mimic exercise, the scan may assess blood flow both at rest and under stress. This aids physicians in determining CFR, a crucial metric for diagnosing CMD. PET is a great option for this type of diagnostic since it can provide precise, realtime data [47,48,49]. The blood vessel problems in CMD patients are not limited to the heart. Studies show that people with CMD also tend to have stiffer arteries throughout their body. This is usually measured by checking pulse wave velocity (PWV), which tells us how fast blood moves through the vessels. Higher PWV means stiffer arteries. CMD patients usually show higher PWV and less ability for their arteries to relax properly, which is called endothelium dependent vasodilation. These findings have been repeated in many studies, confirming that CMD affects more than just the heart’s tiny vessels [50,51]. 

AI Based Imaging Analysis 

In order to identify subtle functional and anatomical patterns linked to coronary microvascular dysfunction (CMD), which underlies microvascular angina (MVA), artificial intelligence (AI) and deep learning (DL) are increasingly being used in cardiac imaging modalities, particularly PET, CMR, and cardiac CT [52].  AI systems can automatically identify microvascular ischemia by extracting and integrating quantitative data from imaging investigations, such as cardiac perfusion maps or flow reserve metrics. DL-based analysis demonstrated better ischemia identification than conventional perfusion indices in a registry of more than 1,600 patients without known CAD undergoing stress myocardial perfusion imaging (MPI) (AUC 0.80 versus 0.78; p < 0.01) [53]. Even when epicardial arteries seem normal, these methods enable the diagnosis of non-obstructive but functionally important CMD.

Biomarkers

1.         Circulating protein biomarkers: Inflammation, Endothelial & Coagulation Markers  A group of inflammatory and endothelial biomarkers, such as TNF-α, IL-6, CRP, and sCD40L, were substantially correlated with CMD, which is defined as reduced coronary flow velocity reserve (CFVR < 2.0), in women with angina but no obstructive CAD. These grouped biomarkers significantly indicated compromised microvascular function, according to principal component analysis [54]. Four vascular biomarkers von Willebrand factor (vWF), GDF-15, tissue-type plasminogen activator (tPA), and Galectin-4 were substantially linked with poor microvascular dilatation in a proteomic investigation of 97 women with CMD evaluated by rubidium-82 PET (MBFR < 2.5)

[55].

2.         Oxidative Stress Biomarkers 

As CMD patients have lower antioxidant capacity than controls, oxidative stress indicators such decreased glutathione have been demonstrated in invasive CMD examinations to independently predict impaired coronary vascular reactivity [56].

3.         Metabolic-Profiling & Machine Learning Signatures

Using multi-omics and machine learning, plasma metabolite profiling of postmenopausal women revealed particular chemical signatures that distinguish CMD patients from controls, providing proof-of-concept for non-invasive metabolic biomarkers in CMD identification [56]. 

4.         Multi-Mechanism Biomarker Reviews 

Endothelial dysfunction, vascular inflammation, and oxidative stress are the three primary domains into which a recent narrative review divides biomarkers for CMD/MVA, highlighting their advantages and disadvantages for clinical application as non-invasive diagnostic tools [58].

MANAGEMENT OF MVA

Intravascular ultrasonography studies have shown that most MVA patients do have some degree of concurrent coronary atherosclerosis [59]. Therefore, for the majority of patients, total control over heavy smoking, hypertension, hyperlipidemia, diabetes, lifestyle modifications, and obesity is recommended in order to lower risk factors. Additionally, the guidelines suggested that the mechanism or pathway failure causing MVA be addressed as part of the treatment. β-blockers, angiotensin-converting enzyme inhibitors (ACE-I), statins, lifestyle modifications, and weight loss are recommended for individuals with anomalous CFR <2.0 or IMR ≥25 units and a negative cholinergic provocation test. Similar to vasospastic angina, microvascular spasm can also be treated [60]. The primary objective of pharmacologic therapies for MVA patients is to manage symptoms and enhance their quality of life. The most often prescribed medications for MVA patients include beta-blockers, nitrates, statins, calcium channel blockers, and angiotensinconverting enzyme inhibitors. Myocardial perfusion and angina are known to be improved by these substances. 

Agents used in MVA

Statins

Beyond their potential to decrease cholesterol by blocking 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, statins have been shown to improve endothelial function by boosting NO bioavailability, having antioxidant qualities, and reducing inflammatory responses [61]. Statins have strong anti-inflammatory effects in addition to their ability to decrease cholesterol [62]. Additionally, a 2011 systematic review demonstrated that statin medication significantly improved peripheral and coronary endothelial function, underscoring its potential application in MVA [63]. Treatment with statins was linked to a significant improvement in endothelial function with a standardized mean difference of 0.66 (95% CI [0.46–0.85]; p<0.001), according to a recent systematic review and meta-analysis of randomized controlled trials evaluating the impact of statins on coronary and peripheral endothelial function [64]. 

Beta-blockers

β-Blockers are first-line treatment for patients with symptomatic CMD particularly when heart rate is raised because they increase diastolic perfusion time and decrease myocardial oxygen demand [65]. Some studies shows that atenolol and propranolol decreases anginal episodes in people with normal coronary arteries when compared to calcium channel blockers or nitrates [66]. Thirdgeneration β-blockers like carvedilol and nebivolol, improve nitric oxide bioavailability and coronary flow reserve (CFR) in ways that go beyond simply lowering heart rate [67]. 

ACE inhibitors

In patients with CMD, ACE medications such as quinapril and enalapril have been used to enhance endothelial-mediated vasomotor responses and CFR, including reversing microvascular remodeling in hypertensive persons [68]. Clinical research and meta- analyses also indicate that ACE inhibitor along with statin therapy improves capacity and quality of life in individuals with microvascular angina [69].

FUTURE PERSPECTIVE AND RESEARCH DIRECTION 

Combination of invasive and non-invasive tests, such as coronary flow reserve (CFR), index of microcirculatory resistance (IMR), cardiac MRI, and PET, with AI-driven multimodal analytics improves detection accuracy and risk, further CMVA research is done for advance precision diagnosis and treatment [70]. In order to find new molecular targets, mechanistic research is dissecting structural and functional pathology, including endothelial dysfunction, remodeling, oxidative stress, inflammation, metabolic syndrome interaction, and vasomotion disorders including microvascular spasm [71]. Pharmacologic therapies employing drugs like ACE inhibitors, statins, ranolazine, and endothelin receptor antagonists are being driven by phenotype-guided precision medicine, as demonstrated by CorMicA stratified therapy and ongoing trials targeting

CMD subgroups [72]. In order to increase results in CMVA populations, research will focus on high-quality RCTs, standardized INOCA/MVA diagnostic criteria, biomarker identification for early screening and monitoring, and integrated multi-target therapy approaches [73].

CONCLUSION 

Coronary microvascular angina represents the paradigm shift in the area of cardiology that shows the complexity of ischemic heart disease. The technologically advanced diagnostics and therapeutic options have showed hope to the sufferers as the understanding of the mechanisms has improved. The integration of molecular analysis and invasive studies into the prediction algorithms for artificial intelligence suggests an era when CMVA would not only be well treated but possibly prevented.

REFERENCES

1. Camici PG, Crea F. Coronary microvascular dysfunction. N Engl J Med. 2007 Feb 22;356(8):830–840. doi: 10.1056/NEJMra061889.
2. Spione F, Arevalos V, Sabaté M, Brugaletta S. Coronary microvascular angina: a stateoftheart review. Front Cardiovasc Med. 2022 Mar 30;9:800918. doi:

10.3389/fcvm.2022.800918

3. Mittal SR. Etiopathogenesis of microvascular angina: caveats in our knowledge. Indian Heart J. 2014 Nov-Dec;66(6):678–681. doi: 10.1016/j.ihj.2014.10.407.
4. Rasmi Y, Majidinia M, Khosravifar F, Kheradmand F. A brief history of cardiac Syndrome X: a biochemical view. J Tehran Heart Cent. 2017 Jan;12(1):46–48. doi: 10.18502/jthc.v12i1.599. PMID: 28469694.
5. Kemp HG Jr, Vokonas PS, Cohn PF, Gorlin R. The anginal syndrome associated with normal coronary arteriograms. Report of a sixyear experience. Am J Med. 1973 Jun;54(6):735–742. doi: 10.1016/00029343(73)900600. PMID: 4705324
6. Cannon RO 3rd, Epstein SE. Microvascular angina as a cause of chest pain with angiographically normal coronary arteries. Am J Cardiol. 1988 Nov 1;61(18):1338– 1343. doi: 10.1016/00029149(88)911800. PMID: 3212628
7. Landmesser U, Drexler H. Cardiac syndrome X and microvascular angina: current state of the art. Circulation. 2005;111(9):1173–1180
8. 8.  van      de        Hoef    TP,      Toya    T,         Siebes M,       Piek     JJ,     Quyyumi         AA,     Camici PG.
9. Prevalence of microvascular disease in patients with angina and nonobstructive coronary arteries: systematic review and metaanalysis. J Am Heart Assoc. 2022;11(10):e023207. doi: 10.1161/JAHA.121.023207. PMID: 35301851.
10. Murthy VL, Naya M, Taqueti VR, et al. Effects of sex on coronary microvascular dysfunction and cardiac outcomes. Circulation. 2014;129(24):2518–2527. doi: 10.1161/CIRCULATIONAHA.113.008507. PMID: 24662919
11. 10.            Gulati  M,       Bairey Merz   CN,      et         al.        Prevalence      of     coronary          microvascular dysfunction among patients with chest pain and nonobstructive coronary artery disease. JACC Cardiovasc Interv. 2015;8(11):1445–1453. PMID: 31344479.
12. Murthy VL, Naya M, Taqueti VR, et al. Effects of sex on coronary microvascular dysfunction and cardiac outcomes. Circulation. 2014;129(24):2518–2527. doi: 10.1161/CIRCULATIONAHA.113.008507. PMID: 24662919.
13. Kaski JC, Rosano GM, et al. Overview indicating that approximately 70% of patients with cardiac syndrome X are female, based on early and contemporary cohorts. Heart. 1995;74(4):302–306. PMID: 15626351.
14. Su J, Liu Y, Yu C, et al. Clinical and pathologic characteristics of coronary microvascular dysfunction. Front Cardiovasc Med. 2023;10:1111721.
15. Astarita C, Nicolai E, Liguori E, Gambardella S, Rumolo S, Maresca FS, et al. Prevalence of metabolic syndrome, insulin resistance, and microvascular angina pectoris in 500 consecutive patients referred to coronarography. Pol Arch Med Wewn. 2008 Dec;118(12):719–726. PMID: 23363255
16. Quyyumi AA, Dakak N, Andrews NP, Kereiakes DJ, Panza JA, Cannon RO 3rd, Epstein SE. Endothelial activation in patients with cardiac syndrome X. Circulation. 2000 Nov 7;102(19):23592365. doi: 10.1161/01.CIR.102.19.2359. PMID: 11067789.
17. Lanza GA, Crea F. Coronary microvascular dysfunction: pathophysiological mechanisms and clinical implications. Nat Rev Cardiol. 2010 Jul;7(7):409–417. doi: 10.1038/nrcardio.2010.96. PMID: 20508501.
18. Bairey Merz CN, Shaw LJ, Reis SE, Bittner V, Kelsey SF, Olson M, et al.Insights from the NHLBI-sponsored women’s ischemia syndrome evaluation (WISE) study: part II: gender differences in presentation, diagnosis, and outcome with regard to gender-based pathophysiology of atherosclerosis and macrovascular and microvascular coronary disease. J Am Coll Cardiol. (2006)47(3 Suppl.):S21–9. doi: 10.1016/J.JACC.2004.12.084
19. Ong P, Camici PG, Beltrame JF, Crea F, Shimokawa H, Sechtem U, Et al.International standardization of diagnostic criteria for microvascular Angina. Int J Cardiol. (2018) 250:16–20. Doi: 10.1016/J.IJCARD.2017.08.068
20. Murthy VL, Naya M, Taqueti VR, Foster CR, Gaber M, Hainer J, et al.Effects of sex on coronary microvascular dysfunction and cardiac outcomes.Circulation. (2014) 129:2518 27. Doi: 10.1161/CIRCULATIONAHA.113.008507
21. Lanza GA, Morrone D, Pizzi C, Tritto I, Bergamaschi L, De Vita A, et al.Diagnostic approach for coronary microvascular dysfunction in patients withChest pain and no obstructive coronary artery disease. Trends CardiovascMed.(2021) 9:S1050- 1738(21)00089-X. doi: 10.1016/j.tcm.2021.08.005
22. M. Bottcher, H. E. Botker, H. Sonne, T. T. Nielsen, and J. Czernin, Endothelium dependent and -independent perfusion reserve and the effect of L-arginine on myocardial perfusion n patients with syndrome X, Circulation, vol. 99, no. 14, pp. 1795–1801, 1999
23. A. M. Zeiher, T. Krause, V. Schächinger, J. Minners, and E. Moser, Impaired endothelium-dependent vasodilation Of coronary resistance vessels is associated with exercise-Induced myocardial ischemia, Circulation, vol. 91, no. 9, pp. 2345– 2352, 1995.
24. K. Egashira, T. Inou, Y. Hirooka, A. Yamada, Y. Urabe, and A. Takeshita, Evidence of impaired endothelium-dependent coronary vasodilatation in patients with angina Pectoris and normal coronary angiograms, New England journal of Medicine, vol. 328, no. 23, pp. 1659–1664, 1993.
25. J. C. Kaski, I. D. Cox, J. R. Crook et al., Differential plasma Endothelin levels in subgroups of patients with angina and Angiographically normal coronary arteries, American Heart Journal, vol. 136, no. 3, pp. 412–417, 1998.
26. I. D. Cox, H. E. Bøtker, J. P. Bagger, H. S. Sonne, B. Ø. Kris-Tensen, and J. C. Kaski, Elevated endothelin concentrations are associated with reduced coronary vasomotor responses In patients with chest pain and normal coronary arterioGrams, Journal of the American College of Cardiology, Vol. 34, no. 2, pp. 455– 460, 1999.
27. Konst, R.E.; Guzik, T.J.; Kaski, J.-C.; Maas, A.H.E.M.; Elias-Smale, S.E. The pathogenic role of coronary Microvascular dysfunction in the setting of other cardiac or systemic conditions. Cardiovasc. Res. 2020, 116, 817–828.
28. I.Tritto, C. Zuchi, and G. Ambrosio, Microvascular angina In different clinical conditions: diabetes and the metabolic Syndrome, in Chest Pain with Normal Coronary Arteries, pp. 137–148, Springer, 13.
29. J.C. Kaski, Overview of gender aspects of cardiac syndrome X, Cardiovascular Research, vol. 53, no. 3, pp. 620–626, 2002
30. Camici PG, Crea F. Coronary microvascular dysfunction. N Engl J Med. 2007;356(8):830–40. https://doi.org/10.1056/NEJMra061889 (PMID: 17314342).
31. Gulati       M,       Levy    PD,      Mukherjee      D,        et         al.        2021     AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR guideline for the evaluation and diagnosis of chest pain: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021;144(22):e368–454
32. Camici     PG,      Crea    F.         Coronary         microvascular dysfunction.    N     Engl    J          Med. 2007;356:830–40
33. Kunadian V, Chieffo A, Camici PG, et al. An EAPCI expert consensus document on ischaemia with non-obstructive coronary arteries in collaboration with european society of cardiology working group on coronary pathophysiology & microcirculation endorsed by coronary vasomotor disorders international study group. Eur Heart J 2020;41(37):3504–20.
34. Lanza, G.A., Barone, L., and Di Monaco, A. 2012. Effect of spinal cord stimulation in patients with refractory angina: evidence from observational studies. Neuromodulation, 15: 542–549; disdcussion 549. doi: 10.1111/j.15251403.2012.00430.x
35. Richardson PJ, Livesley B, Oram S, Olsen EGJ, Armstrong P. Angina pectoris with normal coronary arteries. Transvenous myocardial biopsy in diagnosis. The Lancet. 1974; 304:677–80.
36. Fabio Mangiacapra, Michele Mattia Viscusi, Giuseppe Verolino, et al. Invasive Assessment of Coronary Microvascular Function. J. Clin. Med,2022;11(228):4
37. Doucette JW, Corl PD, Payne HM, et al. Validation of a Doppler guide wire for intravascular measurement of coronary artery flow velocity. Circulation 1992;85:1899–911. https://doi.org/10.1161/01.CIR.85.5.1899; PMID: 1572046
38. de Bruyne B, Pijls NH, Smith L, et al. Coronary thermodilution to assess flow reserve: experimental validation. Circulation 2001;104:2003–6. https://doi. org/10.1161/hc4201.099223; PMID: 11673336
39. AlBadri A, Bairey Merz CN, Johnson BD, et al. Impact of abnormal coronary reactivity on long-term clinical outcomes in women. J Am Coll Cardiol2019;73:684–93. https://doi. org/10.1016/j.jacc.2018.11.040; PMID: 30765035
40. Knuuti J, Wijns W, Saraste A, et al. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 2020;41:407–77. https://doi. org/10.1093/eurheartj/ehz425; PMID: 31504439.
41. Maznyczka          AM, Oldroyd KG,       McCartney      P,         McEntegart     M,     Berry C.          The
42. Potential Use of the Index of Microcirculatory Resistance to Guide Stratification of Patients for Adjunctive Therapy in Acute Myocardial Infarction. JACC Cardiovasc Interv. 2019; 12:951–966 https://doi.org/10.1016/j.jcin.2019.01.246 PMID: 31122353.
43. Fearon WF, Kobayashi Y. Invasive assessment of the coronary microvasculature:the index of microcirculatory resistance. Circ Cardiovasc Interv 2017;10(12). .
44. Cassar, A., Chareonthaitawee, P., Rihal, C.S., Prasad, A., Lennon, R.J., Lerman, L.O., and Lerman, A. 2009. Lack of correlation between noninvasive stress tests and invasive coronary vasomotor dysfunction in patients with nonobstructive coronary artery disease. Circ. Cardiovasc. Interv. 2: 237–244. doi: 10.1161/CIRCINTERVENTIONS. 108.84105
45. Schindler TH, Fearon WF, Pelletier-Galarneau M, et al. Myocardial perfusion PET for the detection and reporting of coronary microvascular dysfunction: a JACC: cardiovascular imaging expert panel statement. JACC Cardiovasc Imaging 2023;16(4):536–48.
46. Panza JA, Laurienzo JM, Curiel RV, et al. Investigation of the mechanism of chest pain in patients with angiographically normal coronary arteries using transesophageal dobutamine stress echocardiography. J Am Coll Cardiol. 1997;29(2):293–301. [PubMed: 9014980]
47. Gan LM, Svedlund S, Wittfeldt A, et al. Incremental value of transthoracic Doppler echocardiography-assessed coronary flow reserve in patients with suspected myocardial ischemia undergoing myocardial perfusion scintigraphy. J Am Heart Assoc 2017;6:e004875. https://doi.org/10.1161/ JAHA.116.004875; PMID: 28420647
48. Prior JO, Allenbach G, Valenta I, Kosinski M, Burger C, Verdun FR, et al. Quantification of myocardial blood flow with 82Rb positron emission tomography: Clinical validation with 15Owater. Eur J Nucl Med Mol Imaging 2012; 39: 1037– 1047. [PubMed: 22398957]
49. Schindler TH, Dilsizian V. Coronary microvascular dysfunction: Clinical considerations and noninvasive diagnosis. JACC Cardiovasc Imaging 2020;13:140– 55. https://doi.org/10.1016/j.jcmg.2018.11.036; PMID: 30982670
50. Schindler TH, Schelbert HR, Quercioli A, Dilsizian V. Cardiac PET imaging for the detection and monitoring of coronary artery disease and microvascular health. JACC Cardiovasc Imaging 2010;3:623–40. https://doi.org/10.1016/j. jcmg.2010.04.007; PMID: 20541718
51. AlBadri A, Lai K, Wei J, et al. Inflammatory biomarkers as predictors of heart failure in women without obstructive coronary artery disease: a report from the NHLBI- sponsored Women’s Ischemia Syndrome Evaluation (WISE). PloS One 2017;12:e0177684. https://doi.org/10.1371/journal.pone.0177684; PMID: 28542263.
52. idawa M, Krzeminska-Pakula M, Peruga JZ, Kasprzak JD. Arterial dysfunction in syndrome X: results of arterial reactivity and pulse wave propagation tests. Heart. 2003; 89(4):422–426. [PubMed: 12639871]
53. Arroyo-Espliguero R, Mollichelli N, Avanzas P, et al. Chronic inflammation and increased arterial stiffness in patients with cardiac syndrome X. Eur Heart J. 2003;4(22):2006–2011. [PubMed: 14613736]
54. Inserra MC, Cannizzaro MT, Passaniti G, et al. Artificial intelligence in cardiovascular CT and MR imaging. Heliyon. 2023 Sep 12;9(9):e19932. doi: 10.1016/j.heliyon.2023.e19932. PMID: 37809686.
55. Arsanjani R, Dey D, Khachatryan T, et al. Artificial intelligencepowered coronary artery disease diagnosis from SPECT myocardial perfusion imaging: a comprehensive deep learning study. J Am Coll Cardiol Imaging.2018;11(11):1654–1663. doi: 10.1016/j.jcmg.2018.01.020. PMID: 29550305
56. Mygind ND, Michelsen MM, Goetze JP, et al. Proinflammatory biomarkers in women with nonobstructive angina pectoris and coronary microvascular dysfunction. Am Heart J. 2019;210:35–46. doi: 10.1016/j.ahj.2019.02.004. PMID:31193994.
57. Mygind ND, Hasbak P, Michelsen MM, et al. Protein biomarkers and coronary microvascular dilatation assessed by rubidium82 PET in women with angina pectoris and no obstructive coronary artery disease. Atherosclerosis. 2018;275:102–109. doi: 10.1016/j.atherosclerosis.2018.06.864. PMID: 29981522.
58. Muñoz Castro S, López Ortega J, Garnacho C, et al. Role of plasma aminothiols in the prediction of coronary microvascular dysfunction and plaque vulnerability.Eur     J          Cardiovasc      Prev     Rehabil.          2011;18(5):828–835.     doi:10.1097/HJR.0b013e32834c50f9. PMID: 21703624.
59. Luidlila Mainzer et al. Identification of circulating diagnostic biomarkers for coronary microvascular disease in postmenopausal women using machinelearning techniques. J Endocr Soc. 2021 May 3;5(Suppl 1):A288. PMID:34070374.
60. Sucato V, Corrado E, Manno G, Amata F, Testa G, Novo G, Galassi AR.
61. Biomarkers of coronary microvascular dysfunction in patients with microvascular angina: a narrative review. Angiology.2022;73(10):900–912. doi:10.1177/00033197211034267. PMID: 34338554.
62. Khuddus M. A., Pepine C. J., Handberg E. M., Bairey Merz C. N., Sopko G., Bavry A. A., Denardo S. J., McGorray S. P., Smith K. M., Sharaf B. L., and Nicholls S. J., An intravascular ultrasound analysis in women experiencing chest pain in the absence of obstructive coronary artery disease: a substudy from the National Heart, Lung and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE), Journal of Interventional Cardiology. (2010) 23, no. 6, 511–519, , 2-s2.0-78650010635, .Knuuti J, Wijns W, Saraste A et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41:407–77. doi:10.1093/eurheartj/ehz425.
63. Davignon J., Beneficial cardiovascular pleiotropic effects of statins, Circulation.(2004) 109, no. 23_suppl_1,
64. Ridker PM, MacFadyen J, Libby P, Glynn RJ. Relation of baseline highsensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of statins in Prevention: an Intervention TrialEvaluating     Rosuvastatin   (JUPITER).     Am      J          Cardiol.           2010;106:204–9.     doi:10.1016/j.amjcard.2010.03.018.
65. Reriani M. K., Dunlay S. M., Gupta B., West C. P., Rihal C. S., Lerman L. O., and Lerman A., Effects of statins on coronary and peripheral endothelial function in humans: a systematic review and meta-analysis of randomized controlled trials, European Journal of Cardiovascular Prevention and Rehabilitation. (2011) 18, no. 5, 704–716, , 2-s2.0-80054867174, .
66. Reriani MK, Dunlay SM, Gupta B et al. Effects of statins on coronary and peripheral endothelial function in humans: a systematic review and meta-analysis of randomized controlled trials. Eur J Cardiovasc Prev Rehabil. 2011;18:704–16. doi: 10.1177/1741826711398430.
67. Kaski JC, Aldama G, Cosín-Sales J. Cardiac syndrome X. Diagnosis and management. Am J Cardiovasc Drugs. 2004;4(3):179–194. doi:0.2165/00129784- 200404030-00004. PMID: 15182208.
68.      Lanza GA, Pedrotti P, Pasceri V, Lucente M, Crea F, Maseri A. Atenolol versus amlodipine versus isosorbide-5-mononitrate on anginal symptoms in syndrome X. Am J Cardiol. 1999;84(7):854–856. doi: 10.1016/S0002-9149(99)00489-3. PMID: 10532591
69. Tzemos N, Lim PO, MacDonald TM. Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study. Circulation. 2001;104(5):511–514. doi: 10.1161/hc3001.093107. PMID:11479243.
70. Mancini GBJ, Henry GC, Macaya C, O’Neill BJ, Pucillo AL, Carere RG, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: The TREND (Trial on Reversing Endothelial Dysfunction) Study. Circulation.1996;94(3):258–     265. doi: 0.1161/01.CIR.94.3.258. PMID: 8759080.Top ofFormBottom of Form
71. Szűcs T, Horváth T, Bánhegyi R, Hüttl K, Csanády M. ACE inhibition and statin combination improves endothelial function and exercise tolerance in patients with cardiac syndrome X: a randomized, placebo-controlled, double-blind study. Eur
72. Heart J. 2004;25(7):618–624. doi: 10.1016/j.ehj.2004.01.002. PMID: 15051287
73. Taqueti VR, Dorbala S. Imaging-based strategies for coronary microvascular disease: Advances toward precision medicine. J Nucl Cardiol. 2021;28(3):1194– 1206. doi: 10.1007/s12350-020-02146-7. PMID: 32601806.
74. Bairey Merz CN, Pepine CJ, Walsh MN, Fleg JL. Ischemia and no obstructive coronary artery disease (INOCA): Developing evidence-based therapies and research agenda for the next decade. Circulation. 2017;135(11):1075–1092. doi: 10.1161/CIRCULATIONAHA.116.024534. PMID: 28289007.
75. Ford TJ, Stanley B, Good R, Rocchiccioli P, McEntegart M, Watkins S, et al. Stratified medical therapy using invasive coronary function testing in angina: the

CorMicA trial.    J          Am      Coll     Cardiol.           2018;72(23     Pt     A):2841–2855do10.1016/j.jacc.2018.09.006. PMID: 30392770.

Taqueti VR, Di Carli MF. Coronary Microvascular Disease Pathogenic Mechanisms and Therapeutic Options: JACC State-of-the-Art Review. J Am Coll Cardiol. 2018;72(21):2625–2641. doi: 10.1016/j.jacc.2018.09.042.PMID:3049610